On March 23rd, the 2018 “Startup in Shanghai” International Innovation and Entrepreneurship Competition was held in the biomedical industry competition at Lingang Pujiang International Science & Technology City. The bio-pharmaceutical industry competition is an important component of the 2018 "Innovation in Shanghai" International Innovation and Entrepreneurship Competition and the "Creating Dreams and Winning Future" Minhang District Innovation and Entrepreneurship Competition, attracting a total of 79 companies from the biopharmaceutical industry in Minhang District.

Lingang Pujiang International Science and Technology City, which combines the functions of a national-level economic and technological development zone, a national-level high-tech industrial development zone, and a national-level export processing zone, has made great strides in the development of high-tech industries with independent innovation as the core, especially The areas of artificial intelligence, high-end equipment manufacturing, environmental protection and new materials, bio-pharmaceutical health, and new energy have formed the advantages of industrial agglomeration. They are the two important core parks for the construction of the Shanghai Science and Innovation Center and the "national industrial and industrial integration demonstration area."

With the support of Shanghai Science and Technology Entrepreneurship Center and the Minhang District Science and Technology Commission, Lingang Pujiang International Science & Technology City has invited over a dozen experts from investment fields to form a review team. The participants took the form of a combination of project presentation and expert review questions. The contestants calmly and confidently responded and demonstrated their own advantages.

In the preparation phase of the event, Lingang Pujiang International Science & Technology City will organize and implement the competition venues, network communication equipment, and members of the judging panel of the competition in accordance with the requirements of the competition. It will also conduct publicity and collection for the enterprises and teams in the park to help entrepreneurs demonstrate innovation and entrepreneurship. The results promote the innovative development of SMEs and entrepreneurial teams.

During the competition, the responsible staff of Lingang Pujiang International Science and Technology City interviewed the participants of five participating companies.

The company aims to develop innovative medical device products that are in line with the clinical needs of Chinese doctors and are competitively priced, and to develop products that suit China's clinical characteristics. This is the first time to participate in the Innovation and Entrepreneurship Competition. Su Yingying, the representative of the competition, said that the game took full advantage of opportunities to communicate with peer companies and conducted brief face-to-face exchanges with review experts, feeling encouraged and benefiting tremendously.

Shanghai Rui Sheng Biotechnology Co., Ltd. is committed to transforming the frontier biological sciences into a vast number of consumers' health service products. The company's brands cover scientific research services, intestinal flora testing and early non-invasive screening of colorectal cancer. Dr. Cai Shunfeng, the representative of the competition, responded to the interview in an eloquent and nebulous manner, fully embodying the company's enthusiasm in the fierce competition of the occasion.

Shanghai Aieride Biotechnology Co., Ltd., with the aim of "making surgery safer", is committed to the research and development and production of leading-edge biotechnology products such as monoclonal-colloidal gold and rapid immunology diagnostic technology. In an interview, Li Huan, the representative of the competition, said that the company is making rapid progress in its dividends from government policies and is also looking forward to achieving greater results in the Lingang Pujiang International Science and Technology City Park.

Shanghai Laiwu Medical Technology Co., Ltd. is the first company in China to complete the entire industrial chain layout of the upper, middle and lower reaches of the regenerative medicine industry. It integrates permanent storage of cell resources, research and development of various cell technologies, and large-scale preparation of cell products, and participates in the national level. Clinical research platform for clinical research, and ultimately achieving the biotechnology industry's bio-tech companies. The project is mainly for the storage, cryopreservation, resuscitation and subsequent immunotherapy of cells.

Shanghai Guoxing Medical Instruments Co., Ltd., the company specializes in the field of clinical in vitro diagnostic products (IVD), the main transformation of foreign clinical diagnostic product technology and independent research and development products and domestic mature clinical diagnostic medical equipment, reagents and consumables.

After the match, the preliminary qualifying promotion project approved by the experts will be selected by the city to participate in the national competition and the finals.

Through the one-by-one review of the project, review experts generally expressed that the quality, technical level, and team quality of the participating projects have continued to increase on the basis of previous years. Some projects have attracted a great deal of interest from investment institutions in the field of response.

At the same time, this competition will link Shanghai's technological innovation funds for small and medium-sized SMEs, science and technology giants engineering, science and technology finance, and other related policies, and will attract more extensive investment and financing institutions and entrepreneurial organizations to provide innovative entrepreneurial services for outstanding projects.